3,653.00
+4.70%
Close of 9 Nov 2026, in ILA
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Brainsway
Its shares trade on Tel Aviv under the ticker BWAY.TA. It has been listed since 24 December 2006. In the fiscal year to 31 December 2025, it reported revenue of $56.5m and net income of $8.3m. At that date it held total assets of $112.9m and shareholders' equity of $73.2m.
Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The firm primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 24 Dec 2006
- Employees
- 96
- Website
- brainsway.com ↗
Leadership
Pay as last reported
- Mr. Amiram BoehmIndependent Chairman of the Board
- Mr. Hadar LevyChief Executive OfficerILS 550,825
- Dr. David ZacutVice Chairman of the Board, since 2006ILS 106,564
- Mr. Ido MaromChief Financial Officer
- Dr. Yiftach RothChief Scientific Officer, since 2006
- Mr. Menachem KleinVice President, General Counsel, Corporate Secretary
- Mr. Eric HirtVice President of US Sales
- Mr. Christopher BoyerVice President - Global MarketingILS 401,535
- Dr. Colleen HanlonVice President - Medical Affairs
- Ms. Moria Ben SoussanVice President - Research & Development
- Dr. Aron TendlerChief Medical Officer
- Prof. Abraham ZangenDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Leading provider of advanced medical solutions for brain disorders.
- High-quality and innovative product portfolio.
- Strong research and development capabilities.
- Established brand and reputation in the medical device industry.
Weaknesses
- Dependence on regulatory approvals for new products.
- Relatively small market share compared to competitors.
- Limited geographic presence.
- High production and marketing costs.
Opportunities
- Increasing global demand for non-invasive brain disorder treatments.
- Expansion into emerging markets with growing healthcare industries.
- Collaborations and partnerships with research institutions and hospitals.
- Technological advancements and potential for new product development.
Threats
- Intense competition from larger medical device companies.
- Stringent regulatory requirements and potential delays in product approvals.
- Economic fluctuations and uncertainty impacting healthcare budgets.
- Potential legal and ethical challenges related to brain disorder treatments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.